Biopharma firm Vyome Holdings posts Q2 net loss
HIND•Outlook
Vyome plans further FDA engagement on VT-1953 clinical development via a Type C meeting.
The company intends to advance new JAK inhibitor assets for autoimmune and inflammatory diseases.
Vyome maintains focus on VT-1953 as its primary development priority while expanding its pipeline.
Q2 results and cash position
US biopharmaceutical firm's Q2 net loss was $720,000, or $0.10 per share.
Cash and cash equivalents rose to $7.9 million as of June 30, 2026.
Clinical and pipeline updates
The company advanced its VT-1953 program and expanded its pipeline with the Impetis agreement.
- Clinical advancement — The company said it advanced its lead VT-1953 program, presenting Phase 2 data showing statistically significant improvements in malodor, daily life impact, and lesion pain, with no treatment-emergent adverse events.
